Dr. Allen O. Eghrari

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy. Dr. Campochiaro is board certified in American Board Of Ophthalmology. Dr. Campochiaro is currently accepting new patients.

Meghan Berkenstock, M.D., is an associate professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute. She specializes in ocular inflammatory and infectious diseases, cataract surgery, and comprehensive ophthalmology. Since joining the faculty of the Wilmer Eye Institute in 2016, she has established a research focus on risk reduction and quality assurance initiatives in the care of patients with uveitis. She has implemented several initiatives to improve laboratory monitoring and understanding barriers to care in patients on immunosuppressive medications. The bulk of her research focuses on identifying ocular adverse events (IRAE) associated with the use of immunotherapy agents in the treatment of systemic malignancies. She is a member and the only ophthalmologist on the National Comprehensive Cancer Network Panel on developing guidelines to treat IRAEs. Dr. Berkenstock is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Scleritis, Episcleritis, Uveitis, Vitrectomy, and Cataract Removal. Dr. Berkenstock is board certified in American Board Of Ophthalmology. Dr. Berkenstock is currently accepting new patients.

Janet Sunness is an Ophthalmologist practicing medicine in Towson, Maryland. Dr. Sunness is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Stargardt Macular Degeneration, Geographic Atrophy, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD). Dr. Sunness is currently accepting new patients.